Use access key #2 to skip to page content.

ChazinWV (< 20)

CRIS, coming up shorted.

Recs

1

June 18, 2014 – Comments (0)

Curis (CRIS) is one of the most heavily shorted biotech stocks. The shorts profited while management secured loans with royalties on the company's only marketed product. Stock offerings and a temporary FDA hold on a dosing study hurt, too. The FDA hold was removed, but the recent change in CEOs took a long time so now debt and the stock's price obstruct access to product development capital. The stock price is driving the company's fundamentals.

0 Comments – Post Your Own

Blog Archive

2014
June (1)
2010
January (1)

Featured Broker Partners


Advertisement